AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
A special meeting of stockholders of Aytu BioScience, Inc. was held on July 26, 2017.
At the meeting, our stockholders took the following actions:
| 1. | Approved an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio of any whole number up to 1-for-20, as determined by our board of directors, at any time before November 14, 2018 (or such other date that is one year after the date of our 2018 annual meeting of stockholders), if and as determined by our board of directors. The vote was 9,707,984 for, 1,580,963 against, 97,749 shares abstaining and no broker non-votes. |
| 2. | Approved an amendment to our 2015 Stock Option and Incentive Plan to (i) increase the number of authorized shares of common stock reserved for issuance thereunder from 2,000,000 to 3,000,000, (ii) increase the number of shares that may be issued as incentive stock options from 2,000,000 to 3,000,000, (iii) increase the maximum number of shares of common stock (A) underlying stock options or stock appreciation rights that may be granted to any one individual during any calendar year period, and (B) granted to any one individual that is intended to qualify as “performance-based compensation” under Section 162(m) of the Internal Revenue Code of 1986, as amended, for any performance cycle from 1,000,000 to 2,000,000, and (iv) in the event that we effect a reverse stock split prior to November 14, 2018 (or such other date that is one year after the date of our 2018 annual meeting of stockholders), immediately after the effective time of such reverse stock split, (A) the maximum number of shares reserved under the Plan will be automatically increased to 3,000,000, (B) the maximum number of shares that may be issued to any type of award will be automatically increased to 3,000,000, (C) the number of shares that may be granted to any one individual during any one calendar year period as stock options or stock appreciation rights will be automatically increased to 2,000,000, and (D) the number of shares that may be issued in the form of incentive stock options will be automatically increased to 3,000,000. The vote was 6,377,095 for, 630,660 against, 26,123 shares abstaining and 4,352,818 broker non-votes. |
| Item 9.01 | Financial Statements and Exhibits. |
| 10.1 | 2015 Stock Option and Incentive Plan, as amended on July 26, 2017. |
AYTU BIOSCIENCE, INC ExhibitEX-10.1 2 v471569_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 AYTU BIOSCIENCE,…To view the full exhibit click here
About AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU)
Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company also markets Primsol (trimethoprim hydrochloride), a trimethoprim-only oral solution for urinary tract infections. The Company’s pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men.
